NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
57 hedge funds and large institutions have $51.4M invested in NeuBase Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
13% less capital invested
Capital invested by funds: $59.3M → $51.4M (-$7.88M)
Holders
57
Holding in Top 10
–
Calls
$508K
Puts
$187K
Top Buyers
| 1 | +$5.99M | |
| 2 | +$3.35M | |
| 3 | +$2.28M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.62M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.37M |
Top Sellers
| 1 | -$4.03M | |
| 2 | -$1.12M | |
| 3 | -$739K | |
| 4 |
Nuveen Asset Management
Chicago,
Illinois
|
-$694K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$610K |